Shots:

• The US FDA has issued EUA for Abbott’s molecular test for COVID-19 and will be used on the m2000 RealTime system which is currently available in hospitals and molecular laboratories in the US
• Abbott will be working with health systems and government authorities to deploy additional m2000 systems and is scaling up production at its US site to reach capacity for 1M test/ week by the end of March
• Abbott’s m2000 molecular platform utilizes PCR technology- amplifying a single piece of DNA to diagnose the patients accurately

Click here ­to­ read full press release/ article | Ref: Abbott | Image: Abbott